These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characterization of gene therapy products and the impact of manufacturing changes on product comparability. Simek SL Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258 [TBL] [Abstract][Full Text] [Related]
3. Mold Control and Detection in Biological Drug Substance Manufacturing Facilities: An Industry Perspective. Bawa A; Asefi S; Ramsey S; Arbesser-Rastburg C; Paul M; Leira F; Landeryou T; Reddy B; Murphy M; Daddis B; Bain D PDA J Pharm Sci Technol; 2017; 71(5):413-420. PubMed ID: 28624776 [No Abstract] [Full Text] [Related]
4. Control of manufacture--the EC point of view. Meyer P Dev Biol Stand; 1992; 79():159-62. PubMed ID: 1286750 [No Abstract] [Full Text] [Related]
5. [Problems raising from the control of biological products employed in medicine. Control of sera, vaccines, and biological products in France]. Desbordes J Ann Ist Super Sanita; 1969; 5(3-4):218-81. PubMed ID: 16089166 [No Abstract] [Full Text] [Related]
6. Biosimilars: opportunity or cause for concern? Roger SD; Mikhail A J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803 [TBL] [Abstract][Full Text] [Related]
7. Product development of probiotics as biological drugs. Sutton A Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718 [TBL] [Abstract][Full Text] [Related]
8. Potential use of the scan statistic for quality control in blood product manufacturing. Lachenbruch PA; Foulkes MA; Williams AE; Epstein JS J Biopharm Stat; 2005; 15(2):353-66. PubMed ID: 15796300 [TBL] [Abstract][Full Text] [Related]
10. FEDESA's point of view: quality, application to IVMPs (immunological veterinary medicinal products). Soulebot JP Dev Biol Stand; 1992; 79():201-11. PubMed ID: 1286759 [No Abstract] [Full Text] [Related]
11. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule. Food and Drug Administration, HHS Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555 [TBL] [Abstract][Full Text] [Related]
12. Experience with validation of clinical trial materials: an inspector's viewpoint. Wolfe L Dev Biol (Basel); 2003; 113():27-33. PubMed ID: 14620849 [TBL] [Abstract][Full Text] [Related]
13. Summary and conclusion. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals. Castle P; Robertson JS Dev Biol Stand; 1999; 99():191-6. PubMed ID: 10404890 [No Abstract] [Full Text] [Related]
14. Do natural compounds need specific drug development? Simon P; Verry M Prog Clin Biol Res; 1988; 280():407-21. PubMed ID: 3051029 [No Abstract] [Full Text] [Related]
15. [Legal basis and significance of manufacturing control in Switzerland]. Fischer P Pharm Acta Helv; 1972; 47(11):629-36. PubMed ID: 4657532 [No Abstract] [Full Text] [Related]
17. An animal origin perspective of common constituents of serum-free medium formulations. Jayme DW Dev Biol Stand; 1999; 99():181-7. PubMed ID: 10404889 [TBL] [Abstract][Full Text] [Related]
19. Characterizing biological products and assessing comparability following manufacturing changes. Chirino AJ; Mire-Sluis A Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163 [TBL] [Abstract][Full Text] [Related]
20. [Importance of control tests of biological products in relation to the use in practice]. Fernández de Castro J Salud Publica Mex; 1979; 21(4):361-8. PubMed ID: 550315 [No Abstract] [Full Text] [Related] [Next] [New Search]